Evidence map›Paper›PMID 36495532›Full record

ArticleHealthcare policy = Politiques de sante2022

Patent "Evergreening" of Medicine-Device Combination Products: A Global Perspective.

Reed F Beall, Tali Glazer, Haris Ahmad, Mikayla Buell, Slane Hahn, Adam R Houston, Aaron S Kesselheim, Jason W Nickerson, Warren Kaplan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Healthcare policy = Politiques de sante, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Healthcare Reform Is Not Yet on the Horizon.Healthcare policy = Politiques de sante · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Reed F BeallAssistant Professor, Department of Community Health Sciences, Cummings School of Medicine, University of Calgary, Calgary, AB.
Tali GlazerResearch Assistant, Department of Community Health Sciences, Cummings School of Medicine, University of Calgary, Calgary, AB.
Haris AhmadResearch Assistant, Department of Community Health Sciences, Cummings School of Medicine, University of Calgary, Calgary, AB.
Mikayla BuellResearch Assistant, Department of Community Health Sciences, Cummings School of Medicine, University of Calgary, Calgary, AB.
Slane HahnResearch Assistant, Department of Community Health Sciences, Cummings School of Medicine, University of Calgary, Calgary, AB.
Adam R HoustonCentre for Health Law, Policy and Ethics, Faculty of Law, University of Ottawa, Ottawa, ON.
Aaron S KesselheimProfessor, Program On Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Jason W NickersonAdjunct Professor, Centre for Health Law, Policy and Ethics, Faculty of Law, University of Ottawa, Clinical Investigator, Bruyère Research Institute, Ottawa, ON.
Warren KaplanClinical Assistant Professor, School of Public Health, Boston University, Boston, MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patenting medicine-delivery devices (inhalers and pens) is controversial when it extends market protections beyond that of the underlying therapeutic agent. We evaluated how common device patenting is, internationally. Method: Using a product sample (n = 88) and an international patent database, we assessed the issue's scope. Results: When comparing the 88 patent portfolios for each product in each country, Canada was found to be among the most impacted, with 90% of the portfolios containing at least one device patent and 35% of the portfolios containing device patents exclusively. Conclusion: Patenting of delivery devices impacts major pharmaceutical manufacturing centres worldwide. International consensus among stakeholders (regulators and payors) is needed on which device modifications represent meaningful clinical value.

Indexed as

Pharmaceutical PreparationsCanadaHumansPharmaceutical Preparations

Identifiers

PMID36495532
PMCPMC9764446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.